July 28, 2014 4:37 PM ET

Biotechnology

Company Overview of Celladon Corporation

Company Overview

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing treatments for heart failure, diabetes, and neurodegenerative diseases. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that results in inadequate pumping of the heart. Its MYDICAR product is developed to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company was founded in 2000 and is headquartered in San D...

12760 High Bluff Drive

Suite 240

San Diego, CA 92130

United States

Founded in 2000

19 Employees

Phone:

858-366-4288

Fax:

858-964-0974

Key Executives for Celladon Corporation

Chief Executive Officer and Director
Age: 58
Total Annual Compensation: $417.5K
Principal Financial and Accounting Officer
Age: 53
Total Annual Compensation: $216.3K
Vice President of Corporate Development & Investor Relations
Age: 43
Total Annual Compensation: $190.4K
Vice President of Clinical Operations
Age: 52
Total Annual Compensation: $216.3K
Compensation as of Fiscal Year 2013.

Celladon Corporation Key Developments

Celladon Corporation Launches Two New Clinical Development Initiatives for MYDICAR

Celladon Corporation announced it has launched two new clinical development initiatives for MYDICAR, its product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies. Celladon plans to initiate a 100 patient Phase 2a trial with MYDICAR in ESRD patients undergoing surgery for AVF creation in preparation for hemodialysis. The trial will evaluate MYDICAR's effect on preventing neointimal hyperplasia and improving blood flow in treated vessels, as a means to enhance the AVF maturation process. AVF maturation failure is a common problem in approximately half of the patients that undergo the procedure. There are currently no U.S. Food and Drug Administration approved products to enhance AVF maturation. Initial results from this study are expected in 2015. The company also plans to initiate a pilot, 24 patient, Phase 1/2 study of MYDICAR in advanced heart failure patients with systolic dysfunction that have been previously excluded from MYDICAR studies in this indication due to pre-existing levels of neutralizing antibodies against the AAV1 vector, which can block MYDICAR's activity. This study will examine whether plasma exchange can remove AAV1 neutralizing antibodies from the circulation in advance of MYDICAR administration. Based on Celladon's database of blood samples to date, the company estimates that approximately 60% of all patients in the United States currently have AAV1 neutralizing antibodies. The company expects to initiate this study in 2014, and initial results are expected in 2015. In addition to these clinical trials, Celladon recently completed enrollment of the 250 patient Phase 2b CUPID2 trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of MYDICAR versus placebo added to a maximal, optimized heart failure regimen in patients with New York Heart Association class III or IV symptoms of chronic heart failure due to systolic dysfunction. The company has received 'breakthrough designation' from the FDA for this MYDICAR program and expects to report results from this trial in April 2015.

Celladon Corporation(NasdaqGM:CLDN) dropped from Russell 2000 Index

Celladon Corporation will be removed from the Russell 2000 Index.

Celladon Corporation(NasdaqGM:CLDN) dropped from Russell 3000 Index

Celladon Corporation will be removed from the Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Galaxy Biotech, LLC United States
Abviva, Inc United States
3D Biomatrix Inc. United States
Zirus, Inc. United States
Nereus Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 15, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celladon Corporation, please visit www.celladon.net. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.